Notes
see Reactions 1772 p3; 803422986
References
Health Canada. Health Canada requests that companies stop distributing ranitidine drugs in Canada while it assesses NDMA; some products being recalled. Internet Document : 17 Sep 2019. Available from: URL: https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/71029a-eng.php
Sandoz. Sandoz Inc. Issues Voluntary Recall of Ranitidine Hydrochloride Capsules 150mg and 300mg Due to an Elevated Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA), in the Product. Internet Document : 23 Sep 2019. Available from: URL: https://www.us.sandoz.com/news/media-releases/sandoz-inc-issues-voluntary-recall-ranitidine-hydrochloride-capsules-150mg-and
Therapeutic Goods Administration. TGA investigation - potential contamination with N-nitrosodimethylamine. Internet Document : 17 Sep 2019. Available from: URL: https://www.tga.gov.au/alert/ranitidine
Medsafe. Medicines containing ranitidine and a potential impurity, N-nitrosodimethylamine (NDMA). Internet Document : 23 Sep 2019. Available from: URL: https://www.medsafe.govt.nz/safety/Alerts/MedicinesAndNDMA.asp
HPRA. Precautionary pharmacy and retail level recall of several batches of a number of Ranitidine medicines in Ireland. Internet Document : 23 Sep 2019. Available from: URL: https://www.hpra.ie/homepage/medicines/safety-notices/item?t=/precautionary-pharmacy-and-retail-level-recall-of-several-batches-of-a-number-of-ranitidine-medicines-in-ireland&id=d26b0c26-9782-6eee-9b55-ff00008c97d0
Rights and permissions
About this article
Cite this article
Ranitidine NDMA contamination: testing and recalls. Reactions Weekly 1773, 2 (2019). https://doi.org/10.1007/s40278-019-68759-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-019-68759-z